[ NATIONAL · IN ]
A central authority alongside state licensing, with GMP set out in the schedule to national drug rules.
SPEQ synthesis for orientation. It does not determine what applies to a specific product, and an adopted version can move without this page moving with it. Confirm the instrument in force with the authority before relying on it.
ASIA-PACIFIC
The Drugs and Cosmetics Act, 1940 and the Drugs and Cosmetics Rules, 1945 made under it. The manufacturing requirements sit in Schedule M to the Rules, which was substantially revised by the Drugs (Amendment) Rules, 2023, notified on 28 December 2023 — a rewrite rather than an update, bringing in a pharmaceutical quality system, quality risk management, qualification and validation, change control, product recall and complaint handling as explicit obligations.
Through a manufacturing licence issued by a State Licensing Authority, with the Central Drugs Standard Control Organisation operating at national level — and the division of labour between them is the thing to get right. Most manufacturing licences are granted and inspected by the state, not the centre; CDSCO handles imports, new drug approvals and central functions, and inspects alongside state authorities. Compliance with revised Schedule M is verified during inspection by CDSCO, the State Licensing Authority and Union Territory administrations.
WHAT TRANSFERS
Little automatically, in either direction, and the asymmetry matters commercially. India is a major supplier to regulated markets, so Indian sites are routinely inspected by foreign authorities — FDA, EU authorities, WHO prequalification — and those outcomes matter to the customers who require them. None of that substitutes for the domestic licence: a site holding an EU GMP certificate still needs its state manufacturing licence, and a WHO-prequalified product still needs Indian registration. Equally, an Indian licence confers nothing abroad.
Manufacturing licences are granted by State Licensing Authorities under the Rules. Organisations that plan around a single national regulator find the actual permission, the actual inspector and the actual timelines sitting at state level, which changes both the process and who has to be engaged.
The 2023 revision introduced a pharmaceutical quality system, quality risk management, qualification and validation, change control and recall obligations as explicit requirements. A quality system built against the earlier Schedule M has real gaps rather than outdated cross-references.
An FDA or EU inspection of an Indian site is evidence for that authority’s market. It does not replace the domestic licence, and the domestic licence does not answer for the foreign market — sites serving both carry both, and reconciling their expectations is ordinary work rather than an exception.
The Act and Rules run both, so the same framework and often the same authority handles product classes that are separately regulated elsewhere. Scope questions are answered inside one instrument rather than by choosing between two.
A State Licensing Authority, under the Drugs and Cosmetics Rules, 1945. The Central Drugs Standard Control Organisation is the national authority, handling imports, new drugs and central functions, and it inspects alongside state authorities — but the manufacturing licence itself is generally a state permission.
The schedule to the Drugs and Cosmetics Rules, 1945 that sets good manufacturing practice requirements — premises, plant, equipment and quality system. It was substantially revised by the Drugs (Amendment) Rules, 2023, notified on 28 December 2023, which introduced a pharmaceutical quality system, quality risk management, qualification and validation, change control, recall and complaint handling as explicit requirements.
No. Foreign inspection outcomes are evidence for those authorities’ markets. A site supplying regulated markets still holds its Indian manufacturing licence from the State Licensing Authority, and is inspected against Schedule M by CDSCO, the State Licensing Authority or Union Territory administration.
CDSCO, State Licensing Authorities and Union Territory administrations, during inspection. Compliance is assessed on inspection rather than by certification, so the evidence has to be present in the system rather than assembled for a submission.
ADOPTED, AT A PINNED VERSION
SPEQ has not decoded a pinned adoption edge here yet. That is a gap in this catalog, not a finding about India: requirements still arrive through the authorities below, and the edition in force is theirs to state.
SPEQ records no harmonizer participation for India. Requirements here are set by the authorities above rather than arriving through a harmonized guide, so evidence prepared for another market does not transfer on that basis.